Escalon® Medical Corp. Receives FDA 510(k) Clearance for the Sonomed Escalon VuPad™

 Escalon® Medical Corp. Receives FDA 510(k) Clearance for the Sonomed Escalon

An innovation in ultrasound you can see and touch

PR Newswire

ARDMORE, Pa., April 4, 2014

ARDMORE, Pa., April 4, 2014 /PRNewswire/ --Escalon Medical Corp. (Nasdaq:
ESMC) today announced that it received U.S. Food and Drug Administration (FDA)
510(k) clearance for its new tablet-based ultrasound imaging system, the
Sonomed Escalon VuPad™.

Sonomed Escalon VuPad(TM)

The VuPad™ combines Sonomed Escalon's superior UBM and newly enhanced B-scan
image quality with an ultra-high-resolution screen that has 25% larger viewing
area than other portable ultrasound devices. Proprietary Enhanced Focus
Rendering™ enables capture of both crisp still images and high-resolution
video clips that can be reviewed frame-by-frame. The VuPad™ is also
remarkably easy to use, thanks to intuitively designed touch screen controls.

"The new VuPad™ is a revolutionary portable ultrasound device that delivers
exceptional image quality in a wide range of ophthalmic applications,"
commented Chief Executive Officer, Richard J. DePiano Jr. "It also
demonstrates the Company's ongoing commitment to developing and delivering new
best-in-class solutions to build on our position as a leader in ophthalmic
ultrasound for over 30 years."

The VuPad™ was previewed at the annual meeting of the American Academy of
Ophthalmology (AAO) in November 2013 and recently garnered additional
attention at the 2014 World Ophthalmic Congress in Tokyo. The VuPad™ will
also be on display at The Exchange 2014, Vision Source's North American
Meeting in Boston, April 9-12, and at the Annual Symposium and Congress of the
American Society of Cataract and Refractive Surgery(ASCRS) in Boston, April

The Company anticipates immediate shipments of VuPad™ systems as orders are
received and manufacturing ramps up to meet demand. CE marking and clearance
by other international regulatory bodies is anticipated in the coming months.

Mr. DePiano added, "We are pleased by the initial indications and the long
term opportunity surrounding the VuPad™ and other new products in our
pipeline; however, we may experience sales fluctuations as we update our
product offering. In addition, planned increases to research and development
expenses as well as increased sales and marketing costs could pressure
financial results."

The VuPad™ offers A-scan, B-scan, and/or UBM modalities in a sleek,
tablet-like package. Key features include portable ergonomic design, elegant
user interface, wireless interconnectivity to EMR's, image management systems,
and printers, multi-touch ultra-high-resolution touch screen with pinch zoom
functionality, and most notably, outstanding image quality and measurement

About Escalon Medical

Founded in 1987, Escalon Medical Corp. (NASDAQ: ESMC)  specializes in the
development, marketing and distribution of ophthalmic diagnostic imaging and
surgical products branded under the Sonomed Escalon name. Products include a
variety of ophthalmic ultrasound, digital imaging and photography, and image
management systems, as well as surgical products including intraocular gases,
fiber optic light guides and sources, and other surgical vitreoretinal
instruments. The Company seeks to grow its ophthalmic business by further
developing and diversifying its product offering through internal development
programs, strategic partnerships, and the acquisition of technology so as to
best leverage the Company's distribution capabilities. The Company has
headquarters in Ardmore, Pennsylvania and research and development,
manufacturing and distribution operations in Lake Success, New York, New
Berlin, Wisconsin and Stoneham, Massachusetts. For additional information
visit and

Forward Looking Statements

This press release contains statements that are considered forward-looking
under the Private Securities Litigation Reform Act of 1995, including
statements about the Company's future prospects. These statements are based on
the Company's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially. The
uncertainties and risks include whether the Company is able to: implement its
growth and marketing strategies, improve upon its operations, including, the
ability to make acquisitions and the integration of any acquisitions it may
undertake, if any, of which there can be no assurance; grow our remaining
ophthalmic business unit, including expanding its product pipeline, obtaining
regulatory and marketing approvals, and commercializing, manufacturing and
shipping new products; improve our financial position; implement cost
reductions; generate cash; and identify, finance and enter into business
relationships and acquisitions. Other factors include uncertainties and risks
related to: new product development, regulatory and marketing approvals,
commercialization, manufacturing and market acceptance of new products;
marketing acceptance of existing products in new markets; research and
development activities, including failure to demonstrate clinical efficacy;
delays by regulatory authorities, scientific and technical advances by the
Company or third parties; introduction of competitive products; ability to
reduce staffing and other costs and retain benefit of prior reductions; third
party reimbursement and physician training, and general economic conditions.
Further information about these and other relevant risks and uncertainties may
be found in the Company's report on Form 10- K for year ended June 30, 2013,
and its other filings with the Securities and Exchange Commission, all of
which are available from the Securities and Exchange Commission as well as
other sources.

Photo -

SOURCE Escalon Medical Corp.

Contact: Richard J. DePiano, Jr, President and CEO, 610-688-6830; Alison
Ziegler, Cameron Associates, 212-554-5469
Press spacebar to pause and continue. Press esc to stop.